Secor Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Secor Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-11,474	Closed	-$1.12M	–	622
2018 Q4	$1.12M	Buy	+11,474	New	+$1.36M	0.15%	203
2018 Q2	–	Sell	-19,150	Closed	-$2.13M	–	676
2018 Q1	$2.13M	Buy	+19,150	New	+$2.29M	0.18%	193
2017 Q4	–	Sell	-20,995	Closed	-$2.94M	–	622
2017 Q3	$2.94M	Sell	20,995 -6,159	-23%	-$837K	0.28%	120
2017 Q2	$3.3M	Buy	+27,154	New	+$3.16M	0.3%	103
2016 Q4	–	Sell	-25,254	Closed	-$3.09M	–	660
2016 Q3	$3.1M	Buy	25,254 +19,247	+320%	+$2.48M	0.34%	89
2016 Q2	$701K	Buy	+6,007	New	+$852K	0.09%	310
2015 Q2	–	Sell	-5,861	Closed	-$1.02M	–	587
2015 Q1	$1.02M	Buy	5,861 +3,556	+154%	+$644K	0.4%	54
2014 Q4	$426K	Buy	+2,305	New	+$427K	0.18%	215

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Secor Capital Advisors's ALXN Position: Q1 2019 in Review

Secor Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 11,474 shares — an estimated $1.12M sold.

Secor Capital Advisors first reported a position in ALXN in Q4 2014 and held it in 8 quarters. The position peaked at $3.3M in Q2 2017. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

Secor Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Secor Capital Advisors sold 11,474 Alexion Pharmaceuticals shares in Q1 2019, an estimated $1.12M.
Secor Capital Advisors first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 8 quarters.
Secor Capital Advisors's Alexion Pharmaceuticals position peaked at $3.3M in Q2 2017.
611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.